Raul Chertkoff

Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

Ari Zimran, Einat Brill‐Almon, Raul Chertkoff et al. · Blood · 2011 · 205 citations · Full text

Life Sciences, Plant Sciences, Glycobiology +13

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

Raphael Schiffmann, Özlem Göker-Alpan, Myrl Holida et al. · Journal of Inherited Metabolic Disease · 2019 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase

Gregory M. Pastores, Мilan Petakov, Pilar Giraldo et al. · Blood Cells Molecules and Diseases · 2014 · 59 citations

Life Sciences, Biochemistry, Glycobiology +7

Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story

Bonita Rup, Sari Alon, Bat-Chen Amit-Cohen et al. · PLoS ONE · 2017 · 52 citations · Full text

Life Sciences, Botany, Immunology +17

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

Eric Wallace, Özlem Göker-Alpan, William R. Wilcox et al. · Journal of Medical Genetics · 2023 · 43 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17